To study the effect of Phalatrikadi Ghanavati and vasadi Ghanavati in Kamala(Jaundice)

A CLINICO-PATHOLOGICAL STUDY ON KAMALA (JAUNDICE) AND ITS COMPARATIVE MANAGEMENT WITH PHALATRIKADI GHANA VATI AND VASADI GHANA VATI - PGVBGV

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/04/033132

Enrollment

Registered

2021-04-26

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K768- Other specified diseases of liver Health Condition 2: K768- Other specified diseases of liver

Interventions

Intervention1: Phalatrikadi Ghana Vati: Phalatrikadi Ghana Vati:- 2 tab (500mg) thrice daily for 15 days with Madhu Control Intervention1: Vasadi Ghana Vati: Vasadi Ghana Vati :- 2 tab (500mg) thr

Eligibility

Inclusion criteria

Inclusion criteria: 1. The patients between the age group of 05-50 years, irrespective of sex. 2. Both fresh and treated individuals, presenting with the symptoms of Kamala like Peetanetrata,Peetamutrata, Peetavarchas, Peetanakha, and Peetatwak are included in research work.

Exclusion criteria

Exclusion criteria: 1. Patients with other systemic diseases like DM,HTN, IHD, HIV,TB 2. Age below 5 above 50 years 3. Pregnant and Lactating mother 4. Obstructive jaundice (Sakhashrita Kamala) 5. Severe and complicated Jaundice

Design outcomes

Primary

Measure	Time frame
To decreases the symptoms- Peetanetrata, Peetamutrata, Peetavarchas, Peetanakha, and PeetatwakTimepoint: 30 days	—

Secondary

Measure	Time frame
Phalatrikadi Ghana Vati is more effective than Vasadi Ghana VatiTimepoint: 31 days	—

Countries

India

Contacts

Public ContactProf Dr Pradip Kumar Panda

Government Ayurvedic College & Hospital, Balangir

drpkpandanidan@rediffmail.com9437150643

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026